Compare · NVO vs XRTX
NVO vs XRTX
Side-by-side comparison of Novo Nordisk A/S (NVO) and XORTX Therapeutics Inc. (XRTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and XRTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 54309.2x XRTX ($3.4M).
- Over the past year, NVO is down 45.7% and XRTX is down 52.2% - NVO leads by 6.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for XRTX).
- NVO has more recent analyst coverage (25 ratings vs 1 for XRTX).
- Company
- Novo Nordisk A/S
- XORTX Therapeutics Inc.
- Price
- $41.01-4.51%
- $2.15-2.49%
- Market cap
- $183.15B
- $3.4M
- 1M return
- -10.44%
- -20.37%
- 1Y return
- -45.66%
- -52.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest XRTX
- SEC Form 6-K filed by XORTX Therapeutics Inc.
- XORTX Announces Closing of US$5 Million Public Offering
- SEC Form 6-K filed by XORTX Therapeutics Inc.
- E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
- SEC Form 424B4 filed by XORTX Therapeutics Inc.
- SEC Form 6-K filed by XORTX Therapeutics Inc.
- XORTX Announces US$5 Million Public Offering
- SEC Form EFFECT filed by XORTX Therapeutics Inc.
- SEC Form 6-K filed by XORTX Therapeutics Inc.
- SEC Form POS AM filed by XORTX Therapeutics Inc.